Rico Timóteo Matthies, Dos Santos Machado Karina, Fernandes Vanessa Pellegrini, Madruga Samanta Winck, Santin Mateus Madail, Petrarca Cristiane Rios, Dumith Samuel Carvalho
Instituto Federal Sul-Rio-Grandense, Corredor das Tropas, 801, Jaguarão - Rio Grande do Sul, Jaguarão, RS, 96300-000, Brazil.
C3 - Centro de Ciências Computacionais, Universidade Federal do Rio Grande, Rio Grande do Sul, Rio Grande, Brazil.
J Med Syst. 2020 Sep 30;44(11):193. doi: 10.1007/s10916-020-01663-x.
Cancer patients are often not sufficiently oriented to manage side effects at home. Sending text messages with self-care guidelines aimed managing side effects is the main objective of this randomized controlled trial. Patients who started outpatient chemotherapy treatment between March and December 2017 at a hospital in southern Brazil were invited to participate in this study and were allocated to the intervention or control group (ratio 1: 1). Each patient in the intervention group received a daily SMS (short message service) with some guidance on management or prevention of side effects. All text messages were sent to the intervention group patients in an automated and tailored way by our app called cHEmotHErApp. Side effects experienced by patients were verified using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30). Results showed intervention group patients experienced fewer side effects compared to the control group in cycle 1 (p < 0.05), in general. In addition, intervention group experienced less nausea in relation to the control group, in the cycle 1 and cycle 2 (p < 0.05). This study indicate text messaging may be a tool for supporting side effect management in patients receiving chemotherapy. This study was enrolled in ClinicalTrials.gov with the identification number NCT03087422. This research was performed in accordance with the Declaration of Helsinki.
癌症患者往往对在家管理副作用缺乏足够的认知。发送包含自我护理指南以管理副作用的短信是这项随机对照试验的主要目标。2017年3月至12月期间在巴西南部一家医院开始接受门诊化疗治疗的患者被邀请参与本研究，并被分配到干预组或对照组（比例为1:1）。干预组的每位患者每天都会收到一条关于副作用管理或预防的短信。所有短信均通过我们名为cHEmotHErApp的应用程序以自动化和个性化的方式发送给干预组患者。使用欧洲癌症研究与治疗组织生活质量问卷核心30（EORTC QLQ-C30）来核实患者所经历的副作用。结果显示，总体而言，干预组患者在第1周期中经历的副作用比对照组少（p<0.05）。此外，干预组在第1周期和第2周期中与对照组相比恶心程度较轻（p<0.05）。本研究表明短信可能是支持化疗患者副作用管理的一种工具。本研究已在ClinicalTrials.gov注册，识别号为NCT03087422。本研究是按照《赫尔辛基宣言》进行的。
